Functional Longevity Labs, Inc. — SEC Form D Filing
Functional Longevity Labs, Inc. filed an SEC Form D on September 21, 2026, reporting $25K raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 21, 2026
- Amount reported
- $25K
- Round stage
- Pre-Seed
- Industry
- Pharmaceuticals
- Website
- https://fll.health/
What the company does
Securities: Simple Agreement for Future Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
People experience an 'Health Gap'—a period between the end of healthy life and the end of life itself—due to the underlying biological mechanisms and individual manifestations of aging, leading to age-related illness, functional decline, and diseases like Alzheimer's.
Solution
Functional Longevity Labs is developing therapies, including a proprietary small molecule (FLL-01) for Alzheimer's disease and dietary supplements (Rejuveceuticals™) for age-related decline, by therapeutically modifying the root mechanisms of aging and specific targets like Tyrosyl-tRNA synthetase (TyrRS/YARS1).
Why now
Advances in geroscience, epigenetic biomarkers, and increased understanding of aging's biological mechanisms now allow for the development of targeted therapies to extend healthspan, moving beyond treating individual age-related diseases.
Verdict
This cleared because the team articulated a credible scientific wedge into the highly speculative longevity market, not because they presented a derisked commercialization strategy. Investors implicitly bet on the potential for novel biological insights to unlock a high-value therapeutic pathway, accepting the significant regulatory and development hurdles. Upside was constrained by the inherent early-stage nature of drug discovery, requiring extensive capital and time for validation, limiting the immediate commercial potential beyond an intellectual property play.
Source: SEC EDGAR Form D filing